Tempest Therapeutics director Simantov resigns from Board effective May 23, 2026

Tempest Therapeutics, Inc.

Ms. Simantov resigned from the Board; no disagreement with company operations or policies.
Separation Agreement waives all accrued and unpaid retainer fees from director compensation program.
Her outstanding stock option awards and share ownership are unaffected; indemnification agreement continues for six years.
Full text of Separation Agreement will be filed with the Company's Q2 2026 10-Q.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Simantov

Director

TPST · Tempest Therapeutics, Inc.

Effective: 2026-05-23
Filed: May 29, 2026, 5:01 PM ET

On May 23, 2026, Ms. Simantov notified Tempest Therapeutics, Inc. (the "Company") of her resignation from the Board of Directors of the Company (the "Board"), effective as of such date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Simantov resigned as Director at Tempest Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On May 23, 2026, Ms. Simantov notified Tempest Therapeutics, Inc. (the "Company") of her resignation from the Board of Directors of the Company (the "Board"), effective as of such date.

View on SEC.gov

Tempest Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-248648

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.